Pasar al contenido principal

DISECCION DE MECANISMOS PATOGENICOS EN LA ENFERMEDAD DE PARKINSON MEDIANTE EL USO DE UN MODELO HUMANO BASADO EN IPSC

PID2019-108792GB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

LRRK2-mutant microglia and neuromelanin synergize to drive dopaminergic neurodegeneration in an iPSC-based Parkinson's disease model

  • Blasco-Agell, Lucas
  • Pons-Espinal, Meritxell
  • Testa, Veronica
  • Roch, Gerard|||0000-0002-9045-0579
  • Montero-Muñoz, Jara
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Baruffi, Valentina
  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Richaud-Patin, Yvonne
  • Jimenez, Senda
  • Cuadros, Thais|||0000-0001-6994-2424
  • Cladera-Sastre, Joana Margalida
  • Compte, Joan|||0000-0001-5447-5122
  • Manglano-Artuñedo, Zoe
  • Ventura, Salvador|||0000-0002-9652-6351
  • Juan, Manel|||0000-0002-3064-1648
  • Tolosa, Eduardo
  • Raya, Ángel|||0000-0003-2189-9775
  • Vila Bover, Miquel|||0000-0002-1352-989X
  • Consiglio, Antonella
Parkinson's disease (PD) is a progressive, incurable neurodegenerative disorder characterized by the loss of neuromelanin (NM)-containing dopamine neurons (DAn) in the substantia nigra of the midbrain. Non-neuronal cells are increasingly recognized as contributors to PD. We generated human microglia-like cells (hMG) from induced pluripotent stem cells (iPSC) derived from patients with LRRK2 PD-causing mutations, gene-corrected isogenic controls, and healthy donors. While neither genotype induced neurodegeneration in healthy DAn, LRRK2 hMG become hyperreactive to LPS stimulation, exhibiting increased cytokine expression, reactive oxygen species, and phagocytosis. When exposed to NM-containing particles, but not α-synuclein fibrils, LRRK2 hMG trigger DAn degeneration, in a process that is prevented by pre-treatment with the immunomodulatory drug ivermectin. Finally, post-mortem analysis of midbrain tissue of LRRK2-PD patients show increased microglia activation around NM-containing neurons, confirming our in vitro findings. Overall, our work highlights NM-activated microglia's role in PD progression, and provides a model for testing therapeutic targets. (Figure presented.).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Parkinson's disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration

  • Carola, Giulia
  • Malagarriga, Daniel
  • Calatayud, Carles
  • Pons Espinal, Meritxell, 1986-
  • Blasco Agell, Lucas
  • Richaud Patin, Yvonne
  • Fernández Carasa, Irene
  • Baruffi, Valentina
  • Beltramone, Santiago
  • Molina, Emilio
  • Dell'Era, Patrizia
  • Toledo Aral, Juan J.
  • Tolosa, Eduard
  • Muotri, Alysson R.
  • García Ojalvo, Jordi
  • Soriano i Fradera, Jordi
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
A deeper understanding of early disease mechanisms occurring in Parkinson's disease (PD) is needed to reveal restorative targets. Here we report that human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons (DAn) obtained from healthy individuals or patients harboring LRRK2 PD-causing mutation can create highly complex networks with evident signs of functional maturation over time. Compared to control neuronal networks, LRRK2 PD patients' networks displayed an elevated bursting behavior, in the absence of neurodegeneration. By combining functional calcium imaging, biophysical modeling, and DAn-lineage tracing, we found a decrease in DAn neurite density that triggered overall functional alterations in PD neuronal networks. Our data implicate early dysfunction as a prime focus that may contribute to the initiation of downstream degenerative pathways preceding DAn loss in PD, highlighting a potential window of opportunity for pre-symptomatic assessment of chronic degenerative diseases., Research from the authors’ laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the MESOBRAIN project from the European Union’s Horizon 2020 research and innovation (grant agreement No. 713140), the Spanish Ministry of Economy and Competitiveness-MINECO (RTI2018-095377-B-100, FIS2016-78507-C2-2-P, PID2019-108842GB-C21) the Spanish Ministry of Economy and Competitiveness-MINECO/AEI/FEDER, UE (BFU2016-80870-P) and the Spanish Ministry of Economy and Competitiveness- AEI/10.13039/501100011033 (PID2019-108792GB-I00), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0024 and RD16/0011/0025), AGAUR (2017-SGR-899 and 2017-SGR-1061), and CERCA Program/Generalitat de Catalunya. M.P.E. was partially supported by a Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR) of the Government of Catalonia (2017 BP 00133). L.B. is the recipient of a pre-doctoral fellowship FPI (BES-2017-080579) from the Spanish Ministry of Economy and Competitiveness (MINECO). G.C. was partially supported by pre-doctoral fellowship from Spanish Economy and Competitiveness-MINECO (BES-2014-069603).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Parkinson’s disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration

  • Carola, G.
  • Malagarriga, D.
  • Calatayud, Carles
  • Pons-Espinal, M.
  • Blasco-Agell, Lucas
  • Richaud-Patin, Y.
  • Fernández-Carasa, Irene
  • Baruffi, V.
  • Beltramone, S.
  • Molina, E.
  • Dell’Era, P.
  • Toledo-Aral, Juan José
  • Tolosa, Eduard
  • Muotri , A. R.
  • García Ojalvo, J.
  • Soriano, J.
  • Raya, A.
  • Consiglio, Antonella
A deeper understanding of early disease mechanisms occurring in Parkinson’s disease (PD) is needed to reveal restorative targets. Here we report that human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons (DAn) obtained from healthy individuals or patients harboring LRRK2 PD-causing mutation can create highly complex networks with evident signs of functional maturation over time. Compared to control neuronal networks, LRRK2 PD patients’ networks displayed an elevated bursting behavior, in the absence of neurodegeneration. By combining functional calcium imaging, biophysical modeling, and DAn-lineage tracing, we found a decrease in DAn neurite density that triggered overall functional alterations in PD neuronal networks. Our data implicate early dysfunction as a prime focus that may contribute to the initiation of downstream degenerative pathways preceding DAn loss in PD, highlighting a potential window of opportunity for pre-symptomatic assessment of chronic degenerative diseases., Research from the authors’ laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the MESOBRAIN project from the European Union’s Horizon 2020 research and innovation (grant agreement No. 713140), the Spanish Ministry of Economy and Competitiveness-MINECO (RTI2018-095377-B-100, FIS2016-78507-C2-2-P, PID2019-108842GB-C21) the Spanish Ministry of Economy and Competitiveness-MINECO/AEI/FEDER, UE (BFU2016-80870-P) and the Spanish Ministry of Economy and Competitiveness- AEI/10.13039/501100011033 (PID2019-108792GB-I00), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0024 and RD16/0011/0025), AGAUR (2017-SGR-899 and 2017-SGR-1061), and CERCA Program/Generalitat de Catalunya. M.P.E. was partially supported by a Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR) of the Government of Catalonia (2017 BP 00133). L.B. is the recipient of a pre-doctoral fellowship FPI (BES-2017-080579) from the Spanish Ministry of Economy and Competitiveness (MINECO). G.C. was partially supported by pre-doctoral fellowship from Spanish Economy and Competitiveness-MINECO (BES-2014-069603)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Implantation of CPT1AM-expressing adipocytes reduces obesity and glucose intolerance in mice

  • Soler-Vázquez, M. Carmen
  • Romero, María del Mar
  • Todorcevic, Marijana
  • Delgado, Katia
  • Calatayud, Carles
  • Benitez-Amaro, Aleyda
  • La Chica Lhoëst, Maria Teresa
  • Mera, Paula
  • Zagmutt, Sebastián
  • Bastias-Pérez, Marianela
  • Ibeas, Kevin
  • Casals, Núria
  • Escolà-Gil, Joan Carles
  • Llorente-Cortés, Vicenta
  • Consiglio, Antonella
  • Serra, Dolors
  • Herrero, Laura
Obesity and its associated metabolic comorbidities are a rising global health and social issue, with novel therapeutic approaches urgently needed. Adipose tissue plays a key role in the regulation of energy balance and adipose tissue-derived mesenchymal stem cells (AT-MSCs) have gained great interest in cell therapy. Carnitine palmitoyltransferase 1A (CPT1A) is the gatekeeper enzyme for mitochondrial fatty acid oxidation. Here, we aimed to generate adipocytes expressing a constitutively active CPT1A form (CPT1AM) that can improve the obese phenotype in mice after their implantation. AT-MSCs were differentiated into mature adipocytes, subjected to lentivirus-mediated expression of CPT1AM or the GFP control, and subcutaneously implanted into mice fed a high-fat diet (HFD). CPT1AM-implanted mice showed lower body weight, hepatic steatosis and serum insulin and cholesterol levels alongside improved glucose tolerance. HFD-induced increases in adipose tissue hypertrophy, fibrosis, inflammation, endoplasmic reticulum stress and apoptosis were reduced in CPT1AM-implanted mice. In addition, the expression of mitochondrial respiratory chain complexes was enhanced in the adipose tissue of CPT1AM-implanted mice. Our results demonstrate that implantation of CPT1AM-expressing AT-MSC-derived adipocytes into HFD-fed mice improves the obese metabolic phenotype, supporting the future clinical use of this ex vivo gene therapy approach., This study was supported by the Spanish Ministry of Science and Innovation (MCIN/AEI) (SAF2017-83813-C3-1-R and PID2020-114953RB-C21 to LH and DS and PID2019-108792GB-I00 supported by MCIN/AEI/10.13039/501100011033 and PDC2021-121051-I00 to AC, co-funded by the European Regional Development Fund [ERDF]), the Biomedical Research Centre in Pathophysiology of Obesity and Nutrition (CIBEROBN) (Grant CB06/03/0001 to LH), the Merck Health Foundation (to LH), the Government of Catalonia (2017SGR278 to DS and 2021SGR00367 to LH), the ERC-2020-PoC to AC, the Marató de TV3 Foundation (201627–30 to DS and 202012–32 to AC) and FIS PI21/01523 (to VLl-C), from Fundación BBVA Ayudas a equipos de investigación 2019 (“Translational Molecular Imaging for Detection of Cholesterol Entrapment in the Vasculature with 68Ga-labeled LRP1-derived Peptides” to VLl-C). VLl-C and JCE-G are part of CIBER Enfermedades Cardiovasculares (CIBERCV; CB16/11/00276) and CIBERDEM (CB07/08/0016), respectively, run by the Instituto de Salud Carlos III. MS-V is a recipient of the Ajut de Personal Investigador Predoctoral en Formació (APIF) doctoral fellowship from the University of Barcelona. AC is a recipient of an ICREA “Academia” Award (Generalitat de Catalunya).‬ AB-A is a fellow granted by the Program (FI19/00205) Contratos predoctorales de formación de investigación en salud_from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. The authors thank Senda Jiménez-Delgado‬ for helping with the molecular work.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

iPSC-based modeling of THD recapitulates disease phenotypes and reveals neuronal malformation

  • Tristán-Noguero, Alba
  • Fernández-Carasa, Irene
  • Calatayud, Carles
  • Bermejo-Casadesús, Cristina
  • Pons-Espinal, Meritxell
  • Colini Baldeschi, Arianna
  • Campa, Leticia
  • Artigas, Francesc
  • Bortolozzi, Analía
  • Domingo-Jiménez, Rosario
  • Ibáñez, Salvador
  • Pineda, Mercè
  • Artuch, Rafael
  • Raya, Ángel
  • García-Cazorla, Àngels
  • Consiglio, Antonella
Tyrosine hydroxylase deficiency (THD) is a rare genetic disorder leading to dopaminergic depletion and early-onset Parkinsonism. Affected children present with either a severe form that does not respond to L-Dopa treatment (THD-B) or a milder L-Dopa responsive form (THD-A). We generated induced pluripotent stem cells (iPSCs) from THD patients that were differentiated into dopaminergic neurons (DAn) and compared with control-DAn from healthy individuals and gene-corrected isogenic controls. Consistent with patients, THD iPSC-DAn displayed lower levels of DA metabolites and reduced TH expression, when compared to controls. Moreover, THD iPSC-DAn showed abnormal morphology, including reduced total neurite length and neurite arborization defects, which were not evident in DAn differentiated from control-iPSC. Treatment of THD-iPSC-DAn with L-Dopa rescued the neuronal defects and disease phenotype only in THDA-DAn. Interestingly, L-Dopa treatment at the stage of neuronal precursors could prevent the alterations in THDB-iPSC-DAn, thus suggesting the existence of a critical developmental window in THD. Our iPSC-based model recapitulates THD disease phenotypes and response to treatment, representing a promising tool for investigating pathogenic mechanisms, drug screening, and personalized management., The authors are indebted to the THD patients who have participated in this study. The authors thank Bernd Kuebler and Begoña Aran from the P-CMR[C] Stem Cell Bank, for generating the THD iPSCs. We would like to thank Marcia Triunfol and João Mello-Vieira at Publicase for their help with this manuscript. Research from the authors' laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL) and ERC 2020-PoC (957581 NeurAntigen), the Spanish Ministry of Economy and Competitiveness-MINECO (PID2019-108792GB-I00, PID2019-105136RB-100, PID2021-123925OB-I00, PDC2021-121051-I00 and RTI2018-095377-B-100), supported by MCIN/AEI/10.13039/501100011033 and “NextGenerationEU/PRTR”, Instituto de Salud Carlos III-ISCIII/ and “Fondo Europeo de desarrollo regional” (FEDER) (Red de Terapia Celular - TerCel RD16/0011/0024, FIS PI15/01082, P118/00111), Agencia Estatal de Investigación-AEI (Unidad de Excelencia María de Maeztu CEX2018-000792-M), AGAUR (2017-SGR-899 and 2017-SGR-1061), Fundació la Marató de TV3 (202012-31 and 202012-32) and CERCA Programme/Generalitat de Catalunya. CC was partially supported by predoctoral fellowship (FPU12/03332) from the Spanish Ministry of Education (MEC). AT-N was partially supported by a PFIS pre-doctoral fellowship (FI14/00641) from the Instituto de Salud Carlos III-ISCIII and 2018BR-IRSJD-CdTorres from Sant Joan de Déu Hospital. AC is a recipient of an ICREA “Academia” Award (Generalitat de Catalunya)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Parkinson's disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration

  • Carola, Giulia
  • Malagarriga, Daniel
  • Calatayud, Carles
  • Pons Espinal, Meritxell, 1986-
  • Blasco Agell, Lucas
  • Richaud Patin, Yvonne
  • Fernández Carasa, Irene
  • Baruffi, Valentina
  • Beltramone, Santiago
  • Molina, Emilio
  • Dell'Era, Patrizia
  • Toledo Aral, Juan J.
  • Tolosa, Eduard
  • Muotri, Alysson R.
  • García Ojalvo, Jordi
  • Soriano i Fradera, Jordi
  • Raya Chamorro, Ángel
  • Consiglio, Antonella
A deeper understanding of early disease mechanisms occurring in Parkinson's disease (PD) is needed to reveal restorative targets. Here we report that human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons (DAn) obtained from healthy individuals or patients harboring LRRK2 PD-causing mutation can create highly complex networks with evident signs of functional maturation over time. Compared to control neuronal networks, LRRK2 PD patients' networks displayed an elevated bursting behavior, in the absence of neurodegeneration. By combining functional calcium imaging, biophysical modeling, and DAn-lineage tracing, we found a decrease in DAn neurite density that triggered overall functional alterations in PD neuronal networks. Our data implicate early dysfunction as a prime focus that may contribute to the initiation of downstream degenerative pathways preceding DAn loss in PD, highlighting a potential window of opportunity for pre-symptomatic assessment of chronic degenerative diseases., Research from the authors’ laboratories is supported by the European Research Council-ERC (2012-StG-311736-PD-HUMMODEL), the MESOBRAIN project from the European Union’s Horizon 2020 research and innovation (grant agreement No. 713140), the Spanish Ministry of Economy and Competitiveness-MINECO (RTI2018-095377-B-100, FIS2016-78507-C2-2-P, PID2019-108842GB-C21) the Spanish Ministry of Economy and Competitiveness-MINECO/AEI/FEDER, UE (BFU2016-80870-P) and the Spanish Ministry of Economy and Competitiveness- AEI/10.13039/501100011033 (PID2019-108792GB-I00), Instituto de Salud Carlos III-ISCIII/FEDER (Red de Terapia Celular - TerCel RD16/0011/0024 and RD16/0011/0025), AGAUR (2017-SGR-899 and 2017-SGR-1061), and CERCA Program/Generalitat de Catalunya. M.P.E. was partially supported by a Beatriu de Pinós fellowship from the Agency for Management of University and Research Grants (AGAUR) of the Government of Catalonia (2017 BP 00133). L.B. is the recipient of a pre-doctoral fellowship FPI (BES-2017-080579) from the Spanish Ministry of Economy and Competitiveness (MINECO). G.C. was partially supported by pre-doctoral fellowship from Spanish Economy and Competitiveness-MINECO (BES-2014-069603).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Implantation of CPT1AM-expressing adipocytes reduces obesity and glucose intolerance in mice

  • Soler Vázquez, M. Carmen
  • Romero, María del Mar
  • Todorcevic, Marijana
  • Delgado, Katia
  • Calatayud, Carles
  • Benítez Amaro, Aleyda
  • La Chica Lhoëst, María Teresa
  • Mera, Paula
  • Zagmutt, Sebastián
  • Bastías Pérez, Marianela Pía
  • Ibeas, Kevin
  • Casals, Núria
  • Escola-Gil, Joan Carles
  • Llorente Cortés, Vicenta
  • Consiglio, Antonella
  • Serra, Dolors
  • Herrero, Laura
This study was supported by the Spanish Ministry of Science and Innovation (MCIN/AEI) (SAF2017-83813-C3-1-R and PID2020-114953RB-C21 to LH and DS and PID2019-108792GB-I00 supported by MCIN/AEI/10.13039/501100011033 and PDC2021-121051-I00 to AC, co-funded by the European Regional Development Fund [ERDF]), the Biomedical Research Centre in Pathophysiology of Obesity and Nutrition (CIBEROBN) (Grant CB06/03/0001 to LH), the Merck Health Foundation (to LH), the Government of Catalonia (2017SGR278 to DS and 2021SGR00367 to LH), the ERC-2020-PoC to AC, the Marato ´ de TV3 Foundation (201627–30 to DS and 202012–32 to AC) and FIS PI21/01523 (to VLl-C), from Fundacion ´ BBVA Ayudas a equipos de inves tigacion ´ 2019 (“Translational Molecular Imaging for Detection of Cholesterol Entrapment in the Vasculature with 68Ga-labeled LRP1-derived Peptides” to VLl-C). VLl-C and JCE-G are part of CIBER Enfer medades Cardiovasculares (CIBERCV; CB16/11/00276) and CIBERDEM (CB07/08/0016), respectively, run by the Instituto de Salud Carlos III. MS-V is a recipient of the Ajut de Personal Investigador Predoctoral en Formació (APIF) doctoral fellowship from the University of Barcelona. AC is a recipient of an ICREA “Academia” Award (Generalitat de Catalunya). AB-A is a fellow granted by the Program (FI19/00205) Contratos predoctorales de formación de investigación en salud_from the Instituto de Salud Carlos III (ISCIII) and co-financed with ERDFs. The authors thank Senda Jim´enez-Delgado for helping with the molecular work., Obesity and its associated metabolic comorbidities are a rising global health and social issue, with novel therapeutic approaches urgently needed. Adipose tissue plays a key role in the regulation of energy balance and adipose tissue-derived mesenchymal stem cells (AT-MSCs) have gained great interest in cell therapy. Carnitine palmitoyltransferase 1A (CPT1A) is the gatekeeper enzyme for mitochondrial fatty acid oxidation. Here, we aimed to generate adipocytes expressing a constitutively active CPT1A form (CPT1AM) that can improve the obese phenotype in mice after their implantation. AT-MSCs were differentiated into mature adipocytes, subjected to lentivirus-mediated expression of CPT1AM or the GFP control, and subcutaneously implanted into mice fed a high-fat diet (HFD). CPT1AM-implanted mice showed lower body weight, hepatic steatosis and serum insulin and cholesterol levels alongside improved glucose tolerance. HFD-induced increases in adipose tissue hypertrophy, fibrosis, inflammation, endoplasmic reticulum stress and apoptosis were reduced in CPT1AM-implanted mice. In addition, the expression of mitochondrial respiratory chain complexes was enhanced in the adipose tissue of CPT1AM-implanted mice. Our results demonstrate that implantation of CPT1AM-expressing AT-MSC-derived adipocytes into HFD-fed mice improves the obese metabolic phenotype, supporting the future clinical use of this ex vivo gene therapy approach., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tetrahydrobiopterin (BH4) treatment stabilizes tyrosine hydroxylase, Rescue of tyrosine hydroxylase deficiency phenotypes in human neurons and in a knock-in mouse model

  • Jung-KC, Kunwar|||0000-0002-6745-7318
  • Tristán Noguero, Alba|||0000-0002-0170-9762
  • Altankhuyag, Altanchimeg
  • Piñol Belenguer, David|||0000-0001-7490-5054
  • Prestegård, Karina S.|||0000-0003-3706-6751
  • Fernandez Carasa, Irene|||0000-0002-8195-3510
  • Colini Baldeschi, Arianna|||0000-0002-8638-3705
  • Sigatulina Bondarenko, Maria
  • García-Cazorla, Angels|||0000-0001-9853-688X
  • Consiglio, Antonella
  • Martinez, Aurora|||0000-0003-1643-6506
Proteostatic regulation of tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, is crucial for maintaining proper brain neurotransmitter homeostasis. Variants of the TH gene are associated with tyrosine hydroxylase deficiency (THD), a rare disorder with a wide phenotypic spectrum and variable response to treatment, which affects protein stability and may lead to accelerated degradation, loss of TH function and catecholamine deficiency. In this study, we investigated the effects of the TH cofactor tetrahydrobiopterin (BH) on the stability of TH in isolated protein and in DAn- differentiated from iPSCs from a human healthy subject, as well as from THD patients with the R233H variant in homozygosity (THDA) and R328W and T399M variants in heterozygosity (THDB). We report an increase in TH and dopamine levels, and an increase in the number of TH+ cells in control and THDA cells. To translate this in vitro effect, we treated with BH a knock-in THD mouse model with Th variant corresponding to R233H in patients. Importantly, treatment with BH significantly improved motor function in these mice, as demonstrated by increased latency on the rotarod test and improved horizontal activity (catalepsy). In conclusion, our study demonstrates the stabilizing effects of BH on TH protein levels and function in THD neurons and mice, rescuing disease phenotypes and improving motor outcomes. These findings highlight the therapeutic potential of BH as a treatment option for THDA patients with specific variants and provide insights into the modulation of TH stability and its implications for THD management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Implantation of CPT1AM-expressing adipocytes reduces obesity and glucose intolerance in mice

  • Soler Vázquez, M. Carmen|||0000-0003-1430-5617
  • Romero, María del Mar|||0000-0001-6274-5743
  • Todorcevic, Marijana
  • Delgado, Katia
  • Calatayud, Carles|||0000-0003-0032-4198
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Mera, Paula|||0000-0001-8941-4637
  • Zagmutt, Sebastian|||0000-0001-6050-4452
  • Bastías Pérez, Marianela|||0000-0003-0098-8090
  • Ibeas, Kevin
  • Casals, Nuria|||0000-0002-6719-4300
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
  • Consiglio, Antonella
  • Serra, Dolors|||0000-0002-4936-4206
  • Herrero, Laura|||0000-0003-4244-4673
Obesity and its associated metabolic comorbidities are a rising global health and social issue, with novel therapeutic approaches urgently needed. Adipose tissue plays a key role in the regulation of energy balance and adipose tissue-derived mesenchymal stem cells (AT-MSCs) have gained great interest in cell therapy. Carnitine palmitoyltransferase 1A (CPT1A) is the gatekeeper enzyme for mitochondrial fatty acid oxidation. Here, we aimed to generate adipocytes expressing a constitutively active CPT1A form (CPT1AM) that can improve the obese phenotype in mice after their implantation. AT-MSCs were differentiated into mature adipocytes, subjected to lentivirus-mediated expression of CPT1AM or the GFP control, and subcutaneously implanted into mice fed a high-fat diet (HFD). CPT1AM-implanted mice showed lower body weight, hepatic steatosis and serum insulin and cholesterol levels alongside improved glucose tolerance. HFD-induced increases in adipose tissue hypertrophy, fibrosis, inflammation, endoplasmic reticulum stress and apoptosis were reduced in CPT1AM-implanted mice. In addition, the expression of mitochondrial respiratory chain complexes was enhanced in the adipose tissue of CPT1AM-implanted mice. Our results demonstrate that implantation of CPT1AM-expressing AT-MSC-derived adipocytes into HFD-fed mice improves the obese metabolic phenotype, supporting the future clinical use of this ex vivo gene therapy approach.